Hide metadata

dc.contributor.authorYoshimura, Noriko
dc.contributor.authorHarada, Nobuhiro
dc.contributor.authorBukholm, Ida
dc.contributor.authorKåresen, Rolf
dc.contributor.authorBørresen-Dale, Anne-Lise
dc.contributor.authorKristensen, Vessela N
dc.date.accessioned2015-10-09T02:12:24Z
dc.date.available2015-10-09T02:12:24Z
dc.date.issued2003
dc.identifier.citationBreast Cancer Res. 2003 Dec 11;6(2):R46
dc.identifier.urihttp://hdl.handle.net/10852/46743
dc.description.abstractIntroduction The expression of the oestrogen receptor (ER) is one of the more important clinical parameters of breast cancer. However, the relationship between the ER and its ligand, oestradiol, and the enzymes that synthesise it are not well understood. The expression of mRNA transcripts of members of the oestradiol metabolic and signalling pathways including the ER was studied in detail. Method mRNA transcripts for aromatase (CYP19), 17-β-hydroxysteroid dehydrogenase I, 17-β-hydroxysteroid dehydrogenase II, ERα, ERβ, steroid sulfatase (STS), oestradiol sulfotransferase (EST), cyclin D1 (CYCLD1) and ERBB2 were fluorometrically quantified by competitive RT-PCR using an internal standard in 155 breast carcinomas. In addition, the transcripts of CYP19 were analysed for alternative splicing/usage of exon 1 and an alternative poly A tail. Results A great variability of expression was observed, ranging from 0 to 2376 amol/mg RNA. The highest levels were observed for STS and EST, and the lowest levels (close to zero) were observed for the 17-β-hydroxysteroid dehydrogenase isoenzymes. The levels of mRNA expression were analysed with respect to clinical and histopathological parameters as well as for disease-free survival. High correlation of the mRNA expression of STS, EST and 17-β-hydroxysteroid dehydrogenase in the tumours suggested a common regulation, possibly by their common metabolite (oestradiol). Hierarchical clustering analysis in the 155 patients resulted in two main clusters, representing the ERα-negative and ERα-positive breast cancer cases. The mRNA expression of the oestradiol metabolising enzymes did not follow the expression of the ERα in all cases, leading to the formation of several subclasses of tumours. Patients with no expression of CYP19 and patients with high levels of expression of STS had significantly shorter disease-free survival time (P > 0.0005 and P < 0.03, respectively). Expression of ERβ mRNA was a better prognostic factor than that of ERα in this material. Conclusion Our results indicate the importance of CYP19 and the enzymes regulating the oestrone sulfate metabolism as factors of disease-free survival in breast cancer, in addition to the well-known factors ER and ERBB2. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
dc.language.isoeng
dc.rightsYoshimura et al., licensee BioMed Central Ltd.
dc.titleIntratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer
dc.typeJournal article
dc.date.updated2015-10-09T02:12:24Z
dc.creator.authorYoshimura, Noriko
dc.creator.authorHarada, Nobuhiro
dc.creator.authorBukholm, Ida
dc.creator.authorKåresen, Rolf
dc.creator.authorBørresen-Dale, Anne-Lise
dc.creator.authorKristensen, Vessela N
dc.identifier.doihttp://dx.doi.org/10.1186/bcr746
dc.identifier.urnURN:NBN:no-50935
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/46743/1/13058_2003_Article_748.pdf
dc.type.versionPublishedVersion
cristin.articleidR46


Files in this item

Appears in the following Collection

Hide metadata